Skip to main content

Dr. Li is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Li's full profile

Already have an account?

  • Office

    Medical Oncology and Therapeutics Research
    1500 East Duarte Road
    Duarte, CA 91010
    Phone+1 626-256-4673
    Fax+1 626-301-8233
  • Is this information wrong?

Education & Training

  • Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2012 - 2015
  • New York Presbyterian Hospital (Cornell Campus)
    New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2009 - 2012
  • Weill Cornell Medicine
    Weill Cornell MedicineClass of 2009

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2015 - 2025
  • NY State Medical License
    NY State Medical License 2012 - 2017
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • A Phase 2 Multi-Institutional Study of Nivolumab for Patients with Advanced Refractory Biliary Tract Cancer  
    Olatunji B Alese, Daneng Li, Amit Mahipal, JAMA Oncology

Authored Content

  • A Phase 2 Multi-Institutional Study of Nivolumab for Patients with Advanced Refractory Biliary Tract CancerMay 2020
  • A Phase 2 Multi-Institutional Study of Nivolumab for Patients with Advanced Refractory Biliary Tract CancerMay 2020

Press Mentions

  • Independence Valued over Survival for Neuroendocrine Tumor Patients
    Independence Valued over Survival for Neuroendocrine Tumor PatientsDecember 30th, 2022
  • Longer Survival Not Top Priority for Some Patients with Cancer
    Longer Survival Not Top Priority for Some Patients with CancerDecember 28th, 2022
  • First Patient Dosed with Experimental Cancer-Killing Virus in New Trial
    First Patient Dosed with Experimental Cancer-Killing Virus in New TrialJune 10th, 2022
  • Join now to see all

Professional Memberships

Hospital Affiliations